Q-omics provides the consensus-scored SNORA3C profile across patient tissues and cancer cell-line models. SNORA3C expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SNORA3C is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SNORA3C RNA expression shows 6,077 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUSC, and STAD as cancer lineages where SNORA3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA3C survival associations across molecular data types. SNORA3C RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA3C RNA expression–survival associations across cancer types. High SNORA3C expression shows unfavorable associations in BRCA, THCA, TGCT and SARC, but favorable associations in BLCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SNORA3C RNA expression.
This table summarizes SNORA3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA3C shows higher tumor expression in LUSC, READ and HNSC. The LUSC box plot shows higher SNORA3C RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p = .006).
This table shows molecular features associated with SNORA3C in patient tissues and cancer cell lines. In patient samples, SNORA3C shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
